PUBLICATIONS
2024:
- A Multicenter Long-Term Cohort Study of Eosinophilic Esophagitis Variants and Their Progression to Eosinophilic Esophagitis Over Time.
Greuter T, et al. Clin Transl Gastroenterol. 2024;15:e00664. doi: 10.14309/ctg.0000000000000664. - Ascending to New Heights for Novel Therapeutics for Eosinophilic Esophagitis.
Hirano I, et al; ASCENT WORKING GROUP. Gastroenterology. 2024;166:1-10. doi: 10.1053/j.gastro.2023.09.004. - Endoscopic Features of Eosinophilic Esophagitis.
Schoepfer AM, et al. Immunol Allergy Clin North Am. 2024;44:197-204. doi: 10.1016/j.iac.2023.12.007 - Novel transcriptomic panel identifies histologically active eosinophilic oesophagitis.
Gueguen E, et al. Gut. 2024;73:1076-1086. doi: 10.1136/gutjnl-2023-331743 - Gastroesophageal reflux disease in 2024.
Dalex M, et al. Rev Med Suisse 2024;20(884):1464-1468. doi: 10.53738/REVMED.2024.20.884.1464. - Design of a phase 3, randomized, double-blind, placebo-controlled, 48-week study to evaluate the efficacy and safety of cendakimab in adult and adolescent patients with eosinophilic esophagitis.
Charriez CM, et al. Contemp Clin Trials. 2024;147:107708. doi: 10.1016/j.cct.2024.107708 - Pharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs.
Schoepfer AM, Safroneeva E. Inflamm Intest Dis. 2024;9(1):199-209. doi: 10.1159/000540275 - Eosinophil Distribution in Eosinophilic Esophagitis and its Impact on Disease Activity and Response to Treatment.
Godat A, et al. Clin Gastroenterol Hepatol. 2024;22(7):1528-1530.e3. doi: 10.1016/j.cgh.2023.12.003. - The Role of Esophageal Physiologic Tests in Eosinophilic Esophagitis.
Wakim El-Khoury J, et al. Inflamm Intest Dis. 2024;9(1):296-303. doi: 10.1159/000542435. - Cohort Profile Update: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS).
El-Khoury JW, et al.Inflamm Intest Dis. 2024;9(1):165-173. doi: 10.1159/000539713 - Pediatric Patients with Eosinophilic Esophagitis and Their Parents Identify Symptoms as the Most Important Treatment Outcome.
von Graffenried T, et al. Int Arch Allergy Immunol. 2024;185(6):527-535. doi: 10.1159/000535242 - Odynophagia and Retrosternal Pain Are Common in Eosinophilic Esophagitis and Associated with an Increased Overall Symptom Severity.
Karpf J, et al. Dig Dis Sci. 2024;69(10):3853-3862. doi: 10.1007/s10620-024-08586-4 - Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: an Open-Label Extension Study.
Biedermann L, et al. Clin Gastroenterol Hepatol. 2024:S1542-3565(24)01088-7. doi: 10.1016/j.cgh.2024.10.034
2023 :
- Monitoring Patients With Eosinophilic Esophagitis in Routine Clinical Practice - International Expert Recommendations.
Arnim UV, et al. Clin Gastroenterol Hepatol 2023;21:2526-2533. doi: 10.1016/j.cgh.2022.12.018. - Dupilumab in Patients with Eosinophilic Esophagitis.
Greuter T, Schoepfer AM. N Engl J Med 2023;388:955-956. doi: 10.1056/NEJMc2300703. - Eosinophilic Esophagitis beyond Eosinophils - an Emerging Phenomenon Overlapping with Eosinophilic Esophagitis: Collegium Internationale Allergologicum (CIA) Update 2023.
Salvador Nunes VS, et al. Int Arch Allergy Immunol 2023;184:411-420. doi: 10.1159/000529910. - Ascending to New Heights for Novel Therapeutics for Eosinophilic Esophagitis.
Hirano I, et al. Gastroenterology 2024;166:1-10. doi: 10.1053/j.gastro.2023.09.004. - Barrett's Esophagus in Eosinophilic Esophagitis in Swiss Eosinophilic Esophagitis Cohort Study (SEECS).
Scherer R, et al. Dig Dis. 2023;41:695-707. doi: 10.1159/000531060. - Eosinophil Distribution in Eosinophilic Esophagitis and its Impact on Disease Activity and Response to Treatment.
Godat A, et al. Clin Gastroenterol Hepatol. 2023 Dec 16:S1542-3565(23)01032-7. doi: 10.1016/j.cgh.2023.12.003. - Histological Phenotyping in Eosinophilic Esophagitis: Localized Proximal Disease Is Infrequent but Associated with Less Severe Disease and Better Disease Outcome.
Heil A, et al. Int Arch Allergy Immunol. 2024;185:63-72. doi: 10.1159/000533815. - Novel targets in EoE: one step forward?
Straumann A, Greuter T. Gut 2023;72:811-812. doi: 10.1136/gutjnl-2022-327770 - Mechanisms and clinical management of eosinophilic oesophagitis: an overview.
Biedermann L, Straumann A. Nat Rev Gastroenterol Hepatol 2023;20:101-119. doi: 10.1038/s41575-022-00691-x.
2022:
- Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS).
Ma C, Schoepfer AM, et al. - J Allergy Clin Immunol 2022 Feb;149(2):659-670. doi: 10.1016/j.jaci.2021.07.001. - Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: A cross-sectional multi-center study.
Greuter T, et al. - Allergy 2022 Jan 29. doi: 10.1111/all.15233. - Reliability and Responsiveness of Endoscopic Disease Activity Assessment in Eosinophilic Esophagitis.
Ma C, et al. - Gastrointest Endosc. 2022 Feb 1:S0016-5107(22)00082-7. doi: 10.1016/j.gie.2022.01.014. - International consensus recommendations for eosinophilic gastrointestinal disease nomenclature.
Dellon ES, et al. - Clin Gastroenterol Hepatol. 2022 Feb 15:S1542-3565(22)00143-4. doi: 10.1016/j.cgh.2022.02.017. - Management of eosinophilic esophagitis associated food impaction in Europe and the United States.
Dis Esophagus. Schreiner P, et al. - 2022 Jan 28:doac003. doi: 10.1093/dote/doac003. - Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial.
Dellon ES, et al. - Clin Gastroenterol Hepatol. 2022 Feb 15:S1542-3565(22)00139-2. doi: 10.1016/j.cgh.2022.02.01. - Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cell-Fibroblast Crosstalk.
Shoda T, et al. - Gastroenterology. 2022 Feb;162(2):439-453. doi: 10.1053/j.gastro.2021.10.016. - A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.
Dellon ES, et al. Gastroenterology. 2022 Jul;163(1):59-76. doi: 10.1053/j.gastro.2022.03.02 - Disease Burden and Unmet Need in Eosinophilic Esophagitis.
Bredenoord AJ, et al. Am J Gastroenterol. 2022 Aug 1;117(8):1231-1241. doi: 10.14309/ajg.0000000000001777 - Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study.
Shoda T, et al. Gastroenterology. 2022 May;162(6):1635-1649. doi: 10.1053/j.gastro.2022.01.022 - A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.
Dellon ES, et al. J Allergy Clin Immunol. 2022 Jul;150(1):33-47. doi: 10.1016/j.jaci.2022.03.01 - Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms After Dilation in Adults With Eosinophilic Esophagitis.
- Safroneeva E, et al. Clin Gastroenterol Hepatol. 2022 Apr;20(4):766-775.e4. doi: 10.1016/j.cgh.2021.05.049
- Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme.
Miehlke S, et al. United European Gastroenterol J. 2022 Apr;10(3):330-343. doi: 10.1002/ueg2.12220. - Close follow-up is associated with fewer stricture formation and results in earlier detection of histological relapse in the long-term management of eosinophilic esophagitis.
Bon L, et al. United European Gastroenterol J. 2022 Apr;10(3):308-318. doi: 10.1002/ueg2.12216 - Endoscopic approach to eosinophilic esophagitis: American Society for Gastrointestinal Endoscopy Consensus Conference.
Aceves SS, et al. Gastrointest Endosc. 2022 Oct;96(4):576-592.e1. doi: 10.1016/j.gie.2022.05.013 - Sex Impacts Disease Activity But Not Symptoms or Quality of Life in Adults With Eosinophilic Esophagitis.
Schreiner P, et al. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1729-1738.e1. doi: 10.1016/j.cgh.2021.11.009 - Diagnostic Delay in Patients With Eosinophilic Esophagitis Has Not Changed Since the First Description 30 Years Ago: Diagnostic Delay in Eosinophilic Esophagitis.
Murray FR, et al. Am J Gastroenterol. 2022 Nov 1;117(11):1772-1779. doi: 10.14309/ajg.0000000000001950. - IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis.
Kaymak T, et al. Gut. 2022 May 25:gutjnl-2022-327166. doi: 10.1136/gutjnl-2022-327166
2021
- Higher educational level in patients with eosinophilic esophagitis: a comparative analysis. Dis Esophagus.
Roth R, et al. - 2021 Sep 9;34(9):doab010. doi: 10.1093/dote/doab010. - Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus.
Ma C, Schoepfer AM, Safroneeva E; COREOS Collaborators. - Gastroenterology. 2021 Sep;161(3):748-755. doi: 10.1053/j.gastro.2021.04.080. - Emerging Therapies for Eosinophilic Gastrointestinal Diseases.
Peterson K, Safroneeva E, Schoepfer A. - J Allergy Clin Immunol Pract. 2021 Sep;9(9):3276-3281. doi: 10.1016/j.jaip.2021.07.031. - Food-induced immediate response of the esophagus-A newly identified syndrome in patients with eosinophilic esophagitis.
Biedermann L, et al. - Allergy. 2021 Jan;76(1):339-347. doi: 10.1111/all.14495. Epub 2020 Aug 19. - Effectiveness and Safety of High- vs Low-Dose Swallowed Topical Steroids for Maintenance Treatment of Eosinophilic Esophagitis: A Multicenter Observational Study
Greuter T, et al. - Clin Gastroenterol Hepatol. 2021 Dec;19(12):2514-2523.e2. doi: 10.1016/j.cgh.2020.08.027. - Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitis.
Schoepfer AM, et al. - Gastrointest Endosc. 2021 Nov;94(5):912-919.e2. doi: 10.1016/j.gie.2021.05.017. - Sex Impacts Disease Activity But Not Symptoms or Quality of Life in Adults With Eosinophilic Esophagitis.
Schreiner P, et al. - Clin Gastroenterol Hepatol. 2021 Nov 16:S1542-3565(21)01221-0. doi: 10.1016/j.cgh.2021.11.009. - Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis.
Dellon ES, et al. - Clin Gastroenterol Hepatol. 2021 Mar;19(3):473-483.e17. doi: 10.1016/j.cgh.2020.03.036. - Systematic Review of Outcome Measures Used in Observational Studies of Adults with Eosinophilic Esophagitis.
Schoepfer AM, et al. Int Arch Allergy Immunol. 2021;182(12):1169-1193. doi: 10.1159/000516898. - Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms After Dilation in Adults With Eosinophilic Esophagitis.
Safroneeva E, et al. - Clin Gastroenterol Hepatol. 2021 May 29:S1542-3565(21)00588-7. doi: 10.1016/j.cgh.2021.05.049.
2020
- Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis Gastroenterology.
Hirano I, et al. - 2020 Jan;158(1):111-122.e10. doi: 10.1053/j.gastro.2019.09.042. - Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.
Straumann A, et al. - Gastroenterology. 2020 Nov;159(5):1672-1685.e5. doi: 10.1053/j.gastro.2020.07.039. - Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).
Aceves S, et al. - J Allergy Clin Immunol. 2020 Jan;145(1):28-37. doi: 10.1016/j.jaci.2019.11.012. - Dilation Modifies Association Between Symptoms and Esophageal Eosinophilia in Adult Patients With Eosinophilic Esophagitis.
Safroneeva E, et al. - Am J Gastroenterol. 2020 Dec;115(12):2098-2102. doi: 10.14309/ajg.0000000000000957. - Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis.
Schreiner P, et al. - Clin Gastroenterol Hepatol. 2020 Oct;18(11):2456-2462. doi: 10.1016/j.cgh.2019.11.057. - Systematic Assessment of Adult Patients' Satisfaction with Various Eosinophilic Esophagitis Therapies.
Safroneeva E, et al. - Int Arch Allergy Immunol. 2020;181(3):211-220. doi: 10.1159/000504846. - Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis.
Hirano I, et al. - Aliment Pharmacol Ther. 2020 Apr;51(8):750-759. doi: 10.1111/apt.15670.
La cohorte suisse de l'EoE est soutenue par les entités suivantes :



